Mar 21, 2012 - their dissemination and surviving properties, usually results in inadequate control and many times, in ... publishes papers that deal significantly with diagnosis and control of plant virus diseases. Of. 164 papers ...... PrincÃpios e
949-973-7588 FAX: 760-720-1467 www.ryanforensicdna.com. Old, but not forgotten... Forensic Serology in the Modern Laboratory by: Suzanna R. Ryan, MS.
the progress made using animal models cannot be understated as it has led to insights into .... lin from healthy blood donors with high titers for HTLV-127 ... Recently, the rab- ..... NF-ÎºB inhibitor, Bay 11â7082,108 reverse transcriptase inhib-.
*Corresponding author: Federal University of Santa Maria,. MsciD/PhD ...... 91(2) 930-937. 26. Papanagiotou HP, Morgano SM, Giordano RA, & Pober R.
Sep 24, 1982 - disseminated gonococcal infection, one Bartholinitis, three epididymitis, and one a rectal abcess. Patients without gonorrhoea. This included ...
Dr. Sam Sheppard was accused of beating his wife to death. - The show âThe Fugitiveâ was based on his life. He said he was asleep in the living room when his wife was attacked and the intruder knocked him unconscious. - It looked bad for him sinc
both the CS and the unconditioned stimulus (US) occurred in such a way that the ... During both delay (n 20) and trace (n 18) condition- ing, participants ... associative strength in delay eyeblink conditioning was described by. Perruchet (1985) ....
primers without careful design does not guarantee genome-wide amplification of the virus. In the second chapter .... The observed NHIPs for all 3 identified isolated error/'N' calls from patient sample 380. 67 ...... of intra-primer secondary structu
Mar 28, 2017 - ISSN:xxxx-xxxx SFJV , an open access journal. SF J Virol ... Division of Vaccine Related Product Applications. Office of Vaccines Research and ...
Microscale Propulsion. Microgravity Combustion and Extinction of Isolated Droplets. Advanced .... in engines that use distillate fuels such as Direct Injection Diesel,. HCCI or gas turbine engines. â¢ n-Decane has some chemical characteristics simil
Integrate theory, computational simulation, and experimental discovery and .... Somuri Prasad ...... technology, which led to development of a comprehensive theory on when certain new transistor- ...... M.R. Gomez, S.A. Slutz, A.B. Sefkow, K.D. Hahn,
Jan 5, 2017 - rigorous educational programs for scientific research training. The span of time ... In light of the federal investment in these activities through the.
Bio-inspired Design of a Flexible Humanoid Armor Suit. Christine Ortiz (ICB) Mary C. Boyce (ISN) Neri Oxman (ISN). P. senegalus pectoral fin. Army Relevance.
Finally, the study showed that quiz performances were significantly higher with the PowerPoint slides than the transparencies. In another study at the University ...
Apr 9, 2003 - Problem Description: – Difficult to control flow of data in peer-to-peer networks. • Movies. • Music. • Computer viruses. • Denial of Service (DoS) attacks ... 0.3 : 1. Extensible Networking Platform. 10. 10 - Applied Research Laborator
Sep 7, 2011 - such as the hand, abdominal wall, face and larynx (Siemionow et al., 2010). ...... performance after transabdominal metroplasty: a review of 157.
O. *Subtask under Environmental Physiology, AMRL Project No. 6-64-12-. 028â Subtask, A ... "take" and capacity of thyroid transplants as well as ultimate cor-.
superconducting phases of bismuth-based cuprates. More broadly, this algorithm can serve to .... Vanadates. â¢ Goal: understand the microscopic electronic mechanisms of phase transitions in VO2. â¢ Moonshot: find a stable parameter regime to separa
Jan 31, 2012 - Celestite is an accessory mineral of calcareous rock, commonly ..... formation (422.9m) displays non-negligible values of CECÎ£ (13.1 ...
(2) In general, the smaller the pitch distance between tones, the ... C. H. Wedell, The nature of the absolute judgment of pitch, /. .... For one thing, above and.
Dec 12, 2005 - 5.3 Transmission of a Naval Offshore Bombardment Observation ...... This project was entirely sponsored by the Office of Naval Research as ...
courts to carry out their prime societal responsibilities .... lineup or the instructions provided to a witness) on ...... reduce false alarms. 7. THE PROSECUTION. After the police obtain a positive identification from the eyewitness that their suspe
Serology: Screening for Vaccine Preventable Diseases Alison M Kesson Infectious Diseases and Microbiology.
History of Vaccination
Vaccination • Immunisation against viral diseases is a triumph of modern science and a triumph of community cooperation and organisation.
Effect of Vaccination on Populations • Smallpox eradicated in 1977 • Poliomyelitis – eradicated from the western hemisphere and many areas • Measles • Rubella • Hepatitis B
Smallpox - Variola • Eradication of smallpox in 1977 • 180 years after Jenner showed cowpox infection prevented subsequent infection by smallpox •
Poliomyelitis • Estimated that without eradication, more than ten million new cases of polio worldwide would manifest themselves between 2005 and 2040.
What vaccine preventable diseases are there?
Bacterial VPDs • • • • • •
Tetanus Diphtheria Pertussis Pneumococcus Meningococcus Haemophilus influenzae B • Tuberculosis
• • • • • •
Typhoid Cholera Botulism Anthrax Plague Q fever
Viral VPDs – routine schedule • • • • • • • •
Polio 1,2,3 Hepatitis B virus Measles Mumps Rubella Varicella zoster virus Rotavirus Influenza A and B
VPDs - other • • • • • •
Hepatitis A virus Respiratory syncytial virus Rabies Smallpox Yellow fever Japanese encephalitis
What is a vaccine?
Background • Vaccination or immunisation is the induction or provision of immunity against an infectious disease. • The immunological basis for vaccination depends upon two central properties of the adaptive immune system; antigen specificity and memory. • The effectiveness of a vaccine is directly related to its ability to induce immunological memory.
Vaccination • Active vaccination is induction of host immune response by administration of antigen – long lasting - years. • Passive vaccination is provision of antibody which provides protective immunity over a relatively short period – weeks to months.
• Vaccines are preparations administered orally or parenterally, which stimulate a specific protective immune response in the recipient without themselves causing diseases. • Vaccines prevent disease (protective immunity) but do not necessarily prevent infection (sterilising immunity). • Viral vaccines are either live (attenuated) or killed. • Attenuated vaccines do not cause disease in immunocompetent individuals.
Vaccine protection • With protection actual infection may occur and generate a booster response. The infection will be quickly aborted due to immunological memory of vaccine-induced immunity not necessarily located at viral entry e.g. inactivated polio vaccine.
What is the immunological response?
The “Primary Response” • The “primary response” occurs after first exposure to an antigen - after a latent period of approx 7 to 10 days circulating antibodies first appear in the blood. • Ig M antibodies with low affinity appear first and may fix complement, making cell lysis and phagocytosis possible. • Later antibodies are of IgG with higher affinity. • The switch for IgM to IgG requires T cell cooperation.
The “Primary Response” • As the titre of IgG rises (after the second week) the titre of IgM falls. • IgG antibodies are produced in large amounts and function in neutralisation, antibodydependent cellular cytotoxicity (ADCC) and fixation of complement. • The antibody titre usually reaches a peak at about 2 to 6 weeks after infection and then gradually falls.
The “Secondary Response” • After a second exposure to the same antigen, a heightened memory immune response occurs usually by 4 to 5 days and depends upon proliferation of both B and T cells e.g. measles and varicella. • This provides immunity and protection against disease.
Mucosal Immunity • Many pathogens replicate on the mucosal surfaces before host invasion and may induce secretory IgA in the respiratory and GIT mucous membranes (e.g. rubella, polio, influenza). • IgA is often neutralising, fixes complement (alternative pathway) and lyses some organisms.
Protection • Some measured immune responses may not themselves confer protective immunity but are correlated with protection and remain as useful markers of protective immunity e.g. IgG to rubella, influenza • Parenteral and inactivated vaccines rarely induce mucosal IgA responses.
How do we detect vaccination or infection?
Diagnosis of Infection • Diagnosis of a viral infection – Demonstration of the virus – Demonstration of viral antigen or nucleic acid.
• This is in the acute phase of diseases 5-20 days after exposure. • Demonstration of virus in tissue from affected organs is usually of diagnostic significance • Exceptions may be adenovirus and enterovirus due to GIT excretion
• Respiratory Syncitial Virus
Ref: White and Fenner 1994
Detection of Disease • Detection of specific antibody has a temporal but not a causal association • Positive or negative predictive value of result depends on the clinical picture and the prevalence of disease in the population.
Diagnosis of Infection • Detection of IgM antibodies • Detection of a rising titre of antibodies in paired specimens • Detection of a single high titre • Detection of antigen • Difficult to distinguish reactivation from primary infection – IgM usually more marked in primary infection.
Diagnosis of Infection • All laboratory findings have to be interpreted in relation to clinical symptoms and signs. • The clinician must provide adequate history. • The laboratory should comment on findings and advise regard further testing.
How do we detect immunity or past infection?
Measurement of Immunity • Response to a vaccine is usually determined by measuring the appearance and/or concentration of specific antibodies in serum. • Measles, mumps, rubella hepatitis B, varicella – circulating antibodies correlate with clinical protection, but only measures the humoral arm of immune response. • Evaluation of persisting antibody has been used to determine duration of vaccine-induced immunity.
Measurement of Immunity • Absence of detectable antibody is not always correlated with lack of protection e.g. VZV, HBV • Antibody levels often fall with time (e.g. measles, rubella, HBV) however, revaccination usually leads to a rapid IgG response with little IgM response indicating persisting protective immunity.
Measurement of Immunity • With some vaccines determining the level of antibody is important to imply protection e.g. rubella. • Detection of CMI which would be very helpful is a research tool only.
Detection of Vaccine Protection • Laboratory testing to determine immunity (IgG) is usually different to determining infection (IgM or IgA). • Most serology performed on serum. • Anticoagulants added to blood often interfere with assays especially complement fixation. • A rise in antibody titre may be due to primary infection, reinfection or reactivation.
Methods Available • A variety of methods is available – – – – – –
• Choice of test depends on the virus, the clinical problem – infection or immunity. • Demonstration of seroconversion or rising titre requires paired specimens 1-3 weeks apart.
• Complement Fixation Titre (CFT)
• Haemagglutination Inhibition titre (HAI)
What is protection? • There is some evidence which can be used to determine that an individual will probably have protection from diseases. • Qualitative detection of IgG e.g. measles, mumps, HAV – Detection of antibody correlates with protection • Quantitative detection of IgG e.g. rubella, HBV
Detection of protection • • • • • • • •
Polio 1,2,3 Hepatitis B virus Measles Mumps Rubella Varicella zoster Rotavirus Influenza A & B
= = = = = = = =
Neutralising antibody titre HBsAb = >10 IU / mL Measles IgG detected Mumps IgG detected Rubella = >10 IU / mL ?? Varicella zoster IgG detected ? Not available CFT not predictive of protection. Use HAI or Neut.
Detection of protection • Hepatitis A virus • Respiratory syncytial virus • Rabies
• Yellow fever
• Japanese encephalitis =
Hepatitis A IgG (Total Ab) CFT not predictive of protection. Rabies antibody – or about to die Evidence of vaccination within 3 years Capture IgM –sensitive (CF, HI) Neutralisation to sort out X-reactions (specific) Protection ??
Case 1 • Term female infant born to P2G1 mum • Wt 1.9kg • Apgars 51, 75 • Palpable rash